← Back to Search

Peptide

Retatrutide for Obesity and Cardiovascular Disease (TRIUMPH-3 Trial)

Phase 3
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have established cardiovascular (CV) disease with at least 1 of the following: prior myocardial infarction, prior ischemic or hemorrhagic stroke, or symptomatic peripheral arterial disease
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 80
Awards & highlights

TRIUMPH-3 Trial Summary

This trial will study the effects of a new drug to help people with obesity and cardiovascular disease. It will last 113 weeks.

Who is the study for?
This trial is for adults with obesity (BMI ≥35) and a history of cardiovascular disease, such as heart attack, stroke, or arterial disease. Participants should have tried to lose weight unsuccessfully before. They can't join if they've had recent significant weight changes, certain surgeries or acute cardiovascular events, use of weight loss drugs within the last 90 days, Type 1 diabetes, or specific hereditary cancer syndromes.Check my eligibility
What is being tested?
The study tests Retatrutide's effectiveness and safety in reducing body weight for those with obesity and CVD. It compares Retatrutide given weekly against a placebo over approximately 113 weeks to see which is better at managing these conditions.See study design
What are the potential side effects?
While the side effects are not detailed here, similar medications often cause digestive issues like nausea or diarrhea; injection site reactions; low blood sugar levels; increased heart rate; headache; fatigue; allergic reactions.

TRIUMPH-3 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have heart disease, including a past heart attack, stroke, or symptoms of poor blood flow in my legs.

TRIUMPH-3 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 80
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 80 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent Change from Baseline in Body Weight
Secondary outcome measures
Change from Baseline in Body Mass Index (BMI)
Change from Baseline in Diastolic Blood Pressure (DBP)
Change from Baseline in Hemoglobin A1c (HbA1c)
+7 more

TRIUMPH-3 Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Retatrutide Dose 2Experimental Treatment1 Intervention
Participants will receive retatrutide SC.
Group II: Retatrutide Dose 1Experimental Treatment1 Intervention
Participants will receive retatrutide subcutaneously (SC).
Group III: PlaceboPlacebo Group1 Intervention
Participants will receive placebo.

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,620 Previous Clinical Trials
3,214,799 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,348 Previous Clinical Trials
413,945 Total Patients Enrolled

Media Library

Retatrutide (Peptide) Clinical Trial Eligibility Overview. Trial Name: NCT05882045 — Phase 3
Cardiovascular Disease Research Study Groups: Retatrutide Dose 1, Retatrutide Dose 2, Placebo
Cardiovascular Disease Clinical Trial 2023: Retatrutide Highlights & Side Effects. Trial Name: NCT05882045 — Phase 3
Retatrutide (Peptide) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05882045 — Phase 3
Cardiovascular Disease Patient Testimony for trial: Trial Name: NCT05882045 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent is Retatrutide Dose 1 a hazard to human health?

"The safety of Retatrutide Dose 1 is rated a 3, signifying that there exists some evidence for its efficacy and multiple trials have demonstrated its security."

Answered by AI

Is this research initiative still recruiting participants?

"The clinical trial in question is no longer recruiting participants, according to information available on clinicialtrials.gov. This study was initially listed on June 30th 2023 and has since been updated for the last time on May 22nd 2023. Nevertheless, there are currently 1385 other trials that are actively looking for individuals to enrol in them."

Answered by AI

How many healthcare centers are currently conducting this research within the city?

"At the moment, this medical trial is enrolling participants from 166 separate sites. These are distributed throughout Covina, Fresno and Los Alamitos as well a multitude of other localities. To reduce travelling costs it's important to pick the clinic that is nearest you."

Answered by AI

Who else is applying?

What state do they live in?
North Carolina
California
Texas
Other
What site did they apply to?
Texas Diabetes & Endocrinology, P.A.
Velocity Clinical Research, Westlake
Palm Research Center Tenaya
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1
2
3+
0

Why did patients apply to this trial?

To help another and myself. I have tried drugs, diets and exercise. my weight is pressing on my hiatel hernia.
PatientReceived no prior treatments
I’ve tried multiple drugs and none of them worked. To learn more about what is going on with my body.
PatientReceived no prior treatments

What questions have other patients asked about this trial?

Is this a paid trial?
PatientReceived 1 prior treatment

How responsive is this trial?

Typically responds via
Email
Phone Call
Average response time
  • < 2 Days
Most responsive sites:
  1. Sleep Therapy Research Center: < 48 hours
  2. Pinnacle Clinical Research: < 48 hours
  3. Northwestern University: < 48 hours
Recent research and studies
clinicaltrials.govStudy
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
2023. "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05882045.
All > Meridian > Honolulu
~1161 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top